COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Aakash Desai(University of Connecticut), Vivek Subbiah(Sarah Cannon), Ishwaria M. Subbiah(The University of Texas MD Anderson Cancer Center), Enrique Grande(MD Anderson Cancer Center Madrid), Aparna Hegde(University of Colorado Cancer Center), Sumanta K. Pal(City of Hope), Roman Groisberg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stephen V. Liu(Georgetown University), Benjamin Solomon(Peter MacCallum Cancer Centre), Marc Matrana(Ochsner Medical Center), Gilberto Morgan(Skåne University Hospital), Toni K. Choueiri(Harvard University), Tomislav Dragovich(The University of Texas MD Anderson Cancer Center), Haeseong Park(Brigham and Women's Hospital), Sant P. Chawla(Sarcoma Oncology Center), Pashtoon Murtaza Kasi(Cornell University), Justin F. Gainor(Harvard University), Balázs Halmos(Montefiore Medical Center), Shumei Kato(Center for Personalized Cancer Treatment), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Alison M. Schram(Memorial Sloan Kettering Cancer Center), Giuseppe Curigliano(European Institute of Oncology), Neeraj Agarwal(University of Utah), Herbert H. Loong(Memorial Sloan Kettering Cancer Center)
Cited by 140
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Colorectal cancer
|The Lancet|2019|5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k